Tanner J. Freeman

Tanner J. Freeman

Allergy and Immunology

200 Lothrop Street, Room A608
Pittsburgh, PA 15213

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 29, 2026

EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.

EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.

Journal: Future oncology (London, England)

Published: June 25, 2026

Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR-Positive Early Breast Cancer.

Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR-Positive Early Breast Cancer.

Journal: Cancer research communications

Published: May 20, 2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 25, 2026

Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.

Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 18, 2025

Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.

Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 24, 2025

AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.

AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.

Journal: NPJ breast cancer

Published: September 08, 2025

Longitudinal ctDNA Surveillance in Older Women with ER+ Breast Cancer to Facilitate Surgical De-Escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.

Longitudinal ctDNA Surveillance in Older Women with ER+ Breast Cancer to Facilitate Surgical De-Escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.

Journal: medRxiv : the preprint server for health sciences

Published: September 02, 2025

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.

Journal: Cancer chemotherapy and pharmacology

Published: May 14, 2025

Intraductal carcinoma of the parotid gland, mixed intercalated duct and oncocytic subtype with mucinous and serous acinar differentiation: cytologic and histologic features of a novel morphology.

Intraductal carcinoma of the parotid gland, mixed intercalated duct and oncocytic subtype with mucinous and serous acinar differentiation: cytologic and histologic features of a novel morphology.

Journal: Virchows Archiv : an international journal of pathology

Published: November 15, 2024

p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy.

p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy.

Journal: Nature cancer

Published: April 17, 2023

Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing.

Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing.

Journal: Endocrine-related cancer

Published: September 28, 2022

Showing 1-12 of 22

Last Updated: 09/26/2026